谨慎从来不是过分的:在治疗性结肠炎的5氨酸衍生物中需要谨慎
Antonietta Gerarda Gravina1, Raffaele Pellegrino2, Alessandro Federico1
1Division of Hepatogastroenterology, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Naples 80138, Italy.
World journal of gastroenterology
|December 8, 2025
概括
在性结肠炎中停止维护5-氨基酸盐可能导致复发. 临床医生应谨慎考虑停止使用这些药物,因为指南只允许在非常特定的患者群体中停止使用这些药物.
科学领域:
- 胃肠病学和肝病学
- 临床药理学 临床药理学
- 炎症性肠病研究研究
背景情况:
- 性结肠炎 (UC) 的管理往往涉及维护治疗与5-aminosalicylates (5-ASA).
- 自发性停止维护5-ASA是需要仔细考虑的临床情景.
- 国际指导方针提供了在UC中停止5-ASA治疗的有限标准.
研究的目的:
- 讨论在性结肠炎中自发停止维护5-氨基酸盐后复发率.
- 探索临床医生在UC患者中启动5-ASA戒断的潜在原因.
- 为了强调在考虑在性结肠炎中停用5-ASA时需要谨慎.
主要方法:
- 关于Atay等人最近的一项研究的评论. 研究UC中的5-ASA戒断.
- 对有关5-ASA停止的临床决策过程的分析.
- 关于在性结肠炎中停止5-ASA治疗的国际指导方针的审查.
主要成果:
- 在性结肠炎中停止维持5-ASA与潜在的复发有关.
- 根据国际指南定义的特定患者子集是5ASA退出策略的唯一候选人.
- 临床医生必须非常小心,因为停止5-ASA治疗的指示很窄.
结论:
- 在性结肠炎中取消维持5-ASA的决定需要仔细评估复发风险.
- 在考虑停止使用5-ASA时,遵守严格的国际指导标准至关重要.
- 可能需要进一步的研究来确定特定UC患者群体的最佳退出策略.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
431
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
431
Drugs for Treatment of Diarrhea-Predominant IBS
599
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
599
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
1.3K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.3K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
461
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
461
Inflammatory Bowel Disease I: Ulcerative Colitis
862
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
862
Drugs Affecting GI Tract Motility: Other Laxatives
992
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
992


